OR WAIT null SECS
Modular containment room at Belfast facility allows studies of biologics and vaccines.
Celerion added a containment room at the Belfast, Northern Ireland, UK facility, the company announced in a press release. The new containment room will allow Celerion to develop programs that require studies utilizing biologics, as well as vaccines with primary and secondary containment.
The modular facility uses a negative-pressure processing room that houses a Biosafety Level (BSL-2) cabinet. The room enables processing of live class 2 and class 3 biological products.
Celerion’s facility in Belfast also has extensive early-stage clinical capabilities based on First-In-Human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic, and gastro-intestinal studies.